Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Vorolanib & Preclinical/Clinical data & Combinations

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Some studies have evaluated its safety and efficacy in combination with other drugs like nivolumab and everolimus. The results of these studies suggest that vorolanib shows promise as a treatment option for certain types of cancers and other conditions
Pedersen et al. 2021 Invest New Drugs 39(5): 1298-1305
Bagegni et al. 2022 Cancer Chemother Pharmacol. 89(4): 487-497
Beckermann et al. 2023 JTO Clin Res Rep. 5(2): 100619…

References (Sources)

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
Beckermann et al. 2023 JTO Clin Res Rep. 5(2): 100619
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Pedersen et al. 2021 Invest New Drugs 39(5): 1298-1305

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Vorolanib & Preclinical/Clinical data & Combinations

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat